FDA approves osteoporosis shot that rebuilds bones at the same rate a teenager's skeleton grows 

On Tuesday, the FDA approved Evenity, the brand name for a drug that can make older women's bones regrow at rates seen in teenagers and cut their risk of spinal fractures by up to 73 percent.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 19 April 2019Source: Journal of Theoretical BiologyAuthor(s): Silvia Trichilo, Stefan Scheiner, Mark Forwood, David M.L. Cooper, Peter PivonkaAbstractThis paper presents a pharmacokinetic/pharmacodynamic (PK/PD) model of the action of PTH(1-34) on bone modelling and remodelling, developed for quantitatively investigating the dose- and administration pattern-dependency of the bone tissue response to this drug. Firstly, a PK model of PTH(1-34) was developed, accounting for administration via subcutaneous injections. Subsequently, the PK model was coupled to a (mechanistic) bone cell populat...
Source: Journal of Theoretical Biology - Category: Biology Source Type: research
Abstract: Estimates indicate 70% of all individuals with HIV will be age 50 or older by 2030. Chronic conditions, including cardiovascular disease, diabetes mellitus, kidney disease, malignancies, neurocognitive disorders, and osteopenia or osteoporosis, occur more frequently in patients with HIV and have become the leading cause of morbidity in this population. NPs play an integral role in helping this population age healthfully.
Source: The Nurse Practitioner - Category: Nursing Tags: Feature: IMMUNE DISORDERS: CE Connection Source Type: research
Conclusions: Once-weekly TPTD administration may facilitate early bony union after acute OVF accompanied by severe osteoporosis. PMID: 31000686 [PubMed - as supplied by publisher]
Source: Asian Spine Journal - Category: Orthopaedics Tags: Asian Spine J Source Type: research
Publication date: Available online 18 April 2019Source: Journal of Sport and Health ScienceAuthor(s): Xin Luan, Xiangyang Tian, Haixin Zhang, Rui Huang, Na Li, Peijie Chen, Ru WangAbstractA growing understanding of the benefits of exercise over the past few decades has prompted researchers to take an interest in the possibilities of exercise therapy. Because each sport has its own set of characteristics and physiological complications that tend to appear during exercise training, the effects and underlying mechanisms of exercise remain unclear. Thus, the first step in probing exercise effects on different diseases is the s...
Source: Journal of Sport and Health Science - Category: Sports Medicine Source Type: research
Excessive alcohol consumption leads to alcohol use disorder. Alcohol is metabolized to acetaldehyde, which is then oxidized to acetic acid by aldehyde dehydrogenases (ALDH), a class of enzymes that facilitate the conversion of aldehydes to their corresponding acids. Among ALDHs, mitochondrial ALDH2 is the primary enzyme involved in the metabolism of acetaldehyde. In addition to its well-known role in ethanol metabolism, recent studies have suggested that ALDH2 dysfunction is associated with a variety of human diseases including cardiovascular diseases, diabetes, neurodegenerative diseases, stroke, cancer, anemia, pain, osteoporosis and aging.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Pigmentation and Melanoma Source Type: research
ConclusionsAlthough denosumab is not generally an appropriate treatment for acquired Fanconi syndrome, it may be useful for patients who have hypophosphatemic osteomalacia due to adefovir dipivoxil-induced Fanconi syndrome associated with excessive bone resorption. However, clinicians should keep in mind that if denosumab is administered to patients with hypophosphatemic osteomalacia accompanied by excessive bone resorption, adequate vitamin D and/or phosphate supplementation should be done before administration of denosumab.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Condition:   Cystic Fibrosis Intervention:   Drug: Denosumab Sponsor:   University of Texas Southwestern Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: Higher rates of bone resorption are associated with a lower stiffness index in Japanese postmenopausal women. These results may indicate that high bone resorption affects bone mass more than bone formation, resulting in a low bone mass. PMID: 30995879 [PubMed - as supplied by publisher]
Source: Annals of Human Biology - Category: Biology Tags: Ann Hum Biol Source Type: research
Condition:   Cystic Fibrosis Intervention:   Drug: Denosumab Sponsor:   University of Texas Southwestern Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsIRW, an egg-derived small bioactive peptide enhances osteoblastic activity and stimulates osteogenesis. The stimulation is primarily due to the activation of PI3K-Akt-RUNX2 pathway and its downstream effectors, accompanied by a secondary collagen synthesis pathway.General significanceOur results revealed the positive effects of tripeptide IRW on regulating osteogenesis and collagen synthesis, indicating its potential for the prevention or treatment of osteoporosis.Graphical abstract
Source: Biochimica et Biophysica Acta (BBA) General Subjects - Category: Biochemistry Source Type: research
More News: Health | Orthopaedics | Osteoporosis | Women